Browsing by Author Gurney, Howard

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 40  next >
Issue DateTitleAuthor(s)Citation
2006Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.Gurney, Howard; Corica, T.; Hayden, L.; Hooton, B.; Korbel, E.; Kristjanson, Linda J; McCaul, K.; Neerhut, G.; Spry, N.A.; Weinstein, S.; Western Clinical School: Medicine (Westmead)Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer., European Journal of Cancer (2005), vol.42,(8),2006,pp 1083-1092
2007Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: possible evidence of graft-versus-tumour effectGottlieb, David; Gurney, Howard; Goodwin, A; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: possible evidence of graft-versus-tumour effect, Internal Medicine Journal, vol.37,(2),2007,pp 127-129
2014Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662Gurney, Howard; Diekstra, MHM; Gelderblom, Hans; Huitema, ADR; Kloth, JSL; Klumpen, H J; Lolkema, MPJK; Mathijssen, Ron Hj; Steeghs, N; Swen, JJ; Van Schaik, Ron H N; Yu, H; Western Clinical School: Medicine (Westmead)Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662, Clinical Pharmacology & Therapeutics, vol.96, 1, 2014,pp 81-89
2017Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access programGurney, Howard; Guminski, Alex; Ng, Siobhan; Parente, Phillip; Parnis, Francis; Westmead Clinical School: MedicineCabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program, Asia-Pacific Journal of Clinical Oncology, vol.13, 6, 2017,pp 391-399
2011Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancerBrown, Christopher; Gebski, Val; Gurney, Howard; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Bacon, M; Donadello, Nicoletta; Friedlander, Michael; Maenpaa, J; Meier, W; Petru, E; Pujade-Lauraine, Eric; Reed, N; Sorio, R; Tulunay, G; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCarboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer, British Journal of Cancer, vol.105, 3, 2011,pp 360-365
2014Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancerGurney, Howard; Parente, Phillip; Parnis, Francis; Western Clinical School: Medicine (Westmead)Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer, Asia-Pacific Journal of Clinical Oncology, vol.10, 3, 2014,pp 205-215
2005Changes of bodyweight and lipids during intermittent maximum androgen blockade (IMAB) in the treatment of advanced prostate cancerBerry, Martin; Byth Wilson, Karen; Gurney, Howard; Woo, Henry; Hayden, L.; Korbel, E.; Spry, N; van Ufford-Mannesse, P.; Medical Radiation Sciences; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); Western Clinical School: SurgeryChanges of bodyweight and lipids during intermittent maximum androgen blockade (IMAB) in the treatment of advanced prostate cancer, Journal of Clinical Oncology, vol.23,(16S (June 1 Supplement)),2005,pp 418S-418S
2017CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaGurney, Howard; Escudier, Bernard; et al, Various; George, Saby; Hammers, Hans J; McDermott, David; Procopio, Giuseppe; Sharma, Padmanee; Sosman, Jeffrey A; Srinivas, Sandhya; Tykodi, Scott S; Westmead Clinical School: MedicineCheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma, European Urology, vol.72, 6, 2017,pp 962-971
2014Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancerBoyer, Michael; Gurney, Howard; Horvath, Lisa; Mahon, Kate; Marx, Gavin; Pavlakis, Nick; Stockler, Martin; Castillo, Lesley; Chiam, K; Clark, Susan J.; Daly, R; Lee, B Y; Lin, H-M; Mallesara, G; Nguyen, Q; Swarbrick, A.; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; School of Public Health: Public Health; Medicine; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreCirculating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer, British Journal of Cancer, vol.110, 10, 2014,pp 2462-2471
2015Clinical perspectives: Practical insights from clinical experience with cabazitaxel in AustraliaGurney, Howard; Bahre, Martina; Ng, Siobhan; Parente, P; Western Clinical School: Medicine (Westmead)Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia, Asia-Pacific Journal of Clinical Oncology, vol.11, 3, 2015,pp 199-207
2010Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized TrialBoland, Amy L.; Boyer, Michael; Gebski, Val; Grimison, Peter; Gurney, Howard; Simes, Robert John; Stockler, Martin; Craft, Paul; Harvey, V; Levi, John; Lewis, Craig; Olver, Ian N; Thomson, Damien; Toner, Guy C.; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreComparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial, Journal of the National Cancer Institute, vol.102, 16, 2010,pp 1253-1262
2004Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving ChemotherapyBalleine, Rosemary; Clarke, Christine; Gurney, Howard; Liddle, Christopher; Wong, Mark; Collins, Michael; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstituteCyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy, Clinical Pharmacology & Therapeutics, vol.75,(6),2004,pp 529-538
2017Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survivalPatel, Manish; Smith, David; Bang, Albert; Beattie, Kieran; Gurney, Howard; Westmead Clinical School: Surgery; School of Public Health: Public HealthCytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival, Cancer Medicine, vol.6, 10, 2017,pp 2188-2193
2017A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancerGurney, Howard; Horvath, Lisa; Hoy, Andrew; Marx, Gavin; Stockler, Martin; Briscoe, Karen; Daly, Roger; Lin, Hui-Ming; Mahon, Kate; Mallesara, Girish; Meikle, Peter; Mundra, Piyushkumar; Parton, Robert G.; Spielman, Calan; Weir, Jacquelyn; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; School of Medical Sciences: Physiology; SAHCS: Medicine; NH&MRC Clinical Trials CentreA distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer, International Journal of Cancer, vol.141, 10, 2017,pp 2112-2120
2015Doctor-patient communication: a study of Australian ethnic urological cancer patientsCerimagic, Sabina; Patel, Manish; Ahmadi, Nariman; Gurney, Howard; Western Clinical School: Surgery; Western Clinical School: SurgeryDoctor-patient communication: a study of Australian ethnic urological cancer patients, International Journal of Human Rights in Healthcare, vol.8, 2, 2015,pp 82-91
2016Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE studyBalleine, Rosemary; Gao, Bo-Fu; Gebski, Val; Gurney, Howard; Hui, Rina; Kefford, Richard (Rick); Lee, Clara; Liddle, Christopher; Menzies, Alexander Maxwel; Provan, Pamela; Wilcken, Nicholas; Wong, Ka (Mark); Ali, Sayed Sahanawaz; Balakrishnar, Bavanthi; Coulter, Sally A.; Fox, Peter; Lynch, Jodi; Yeap, Shang Heng; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Western Clinical School (Westmead): Office; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead)Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study, Clinical Cancer Research, vol.22, 13, 2016,pp 3164-3171
2017Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoringGebski, Val; Liddle, Christopher; Balakrishnar, Bavanthi; Chan, Mathew; Coulter, Sally A.; Fox, Peter; Gurney, Howard; Sabanathan, Dhanusha; Zhang, Alison; NH&MRC Clinical Trials Centre; Westmead Clinical School: MedicineDose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring, Cancer Chemotherapy and Pharmacology, vol.80, 2, 2017,pp 385-393
2016The effect of pulmonary function testing on bleomycin dosing in germ cell tumoursGrimison, Peter; Roncolato, Felicia; Stockler, Martin; Chatfield, Mark; Friedlander, Michael; Gurney, Howard; Houghton, Baerin B; Rosenthal, Mark; Thomson, Damien; Toner, Guy; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreThe effect of pulmonary function testing on bleomycin dosing in germ cell tumours, Internal Medicine Journal, vol.46, 8, 2016,pp 893-898
2012Evidence for Therapeutic Drug Monitoring of Targeted Anticancer TherapiesClements, Arthur; Gao, Bo-Fu; Gurney, Howard; Balakrishnar, Bavanthi; WONG, Mark; Yeap, S; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies, Journal of Clinical Oncology, vol.30, 32, 2012,pp 4017-4025
2013Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2Church, William; Cui, Pei-Hong; Gurney, Howard; Jodal, Andreas; Murray, Michael; Wong, Ka (Mark); Zheng, Jian; Zhou, Fanfan; Zhu, Ling; Pharmacy; Pharmacy; Western Clinical School: Medicine (Westmead); Pharmacy; School of Medical Sciences: Pharmacology; Western Clinical School: Medicine (Westmead); Pharmacy; Pharmacy; Central Clinical School: Save Sight & Eye Health Inst.Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2, The AAPS Journal, vol.15, 4, 2013,pp 1099-1108